12:00 AM
 | 
Mar 15, 2012
 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information
Endocrine/metabolic disease
Diabetes; obesity Cannabinoid CB1 receptor (CNR1)

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >